Citation:Lara PN Jr, Chansky K, Davies AM, Franklin WA, Gumerlock PH, Guaglianone PP, et al 2006

From Cancer Guidelines Wiki

Citation


Lara PN Jr, Chansky K, Davies AM, Franklin WA, Gumerlock PH, Guaglianone PP, et al. Bortezomib (PS-341) in relapsed or refractory extensive stage small cell lung cancer: a Southwest Oncology Group phase II trial (S0327). J Thorac Oncol 2006 Nov;1(9):996-1001 Available from: http://www.ncbi.nlm.nih.gov/pubmed/17409985.



Critical appraisals

Critical appraisal linkClinical questionAssigned toStatus
What is the optimal second-line therapy in patients with extensive stage small cell lung cancer?Associate Professor Michael Michael MBBS(Hons), BSc(Hons), MD, FRACPcompleted

Compare quality appraisals for each clinical question

  • [[Clinical question:What is the optimal second line therapy in patients with extensive stage small cell lung cancer?|
    Invalid title «<span class="smw-format list-format "><span class="smw-row"><span class="smw-field"><span class="smw-value">Clinical question:What is the optimal second line therapy in patients with extensive stage small cell lung cancer?</span></span></span></span>»
    ]] (compare critical appraisals)

Cited by

  1. What is the optimal second-line therapy in patients with extensive stage small cell lung cancer?